A business in context

GRCE research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-14 · 0001493152-26-047473

  2. 4 · Ownership change

    Report date 2026-10-08 · 0001493152-26-046899

  3. 4 · Ownership change

    Report date 2026-10-01 · 0001493152-26-045809

  4. 4 · Ownership change

    Report date 2026-09-29 · 0001493152-26-045358

  5. 4/A · Ownership change

    Report date 2026-09-21 · 0001493152-26-045347

  6. 4 · Ownership change

    Report date 2026-09-21 · 0001493152-26-043996

  7. 4 · Ownership change

    Report date 2026-09-17 · 0001140361-26-037246

  8. 4 · Ownership change

    Report date 2026-09-17 · 0001140361-26-037245

  9. 8-K · Current report

    Report date 2026-09-17 · 0001140361-26-037114 · Items 5.07

  10. 8-K · Current report

    Report date 2026-08-13 · 0001140361-26-032644 · Items 2.02,9.01

  11. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001140361-26-032632

  12. 8-K · Current report

    Report date 2026-08-04 · 0001140361-26-031671 · Items 1.01,3.02,8.01,9.01

  13. DEF 14A · Proxy statement

    Report date 2026-09-17 · 0001140361-26-029889

  14. 8-K · Current report

    Report date 2026-07-28 · 0001140361-26-029837 · Items 8.01,9.01

  15. 8-K · Current report

    Report date 2026-06-18 · 0001140361-26-025669 · Items 8.01,9.01

  16. 8-K · Current report

    Report date 2026-06-18 · 0001140361-26-025667 · Items 2.02,9.01

  17. 10-K · Annual report

    Report date 2026-03-31 · 0001140361-26-025662

  18. 8-K · Current report

    Report date 2026-06-01 · 0001140361-26-024269 · Items 5.02,9.01

  19. 8-K · Current report

    Report date 2026-04-27 · 0001140361-26-016834 · Items 8.01,9.01

  20. 8-K · Current report

    Report date 2026-04-23 · 0001140361-26-016324 · Items 8.01,9.01

  21. 8-K · Current report

    Report date 2026-02-12 · 0001140361-26-004927 · Items 2.02,9.01

  22. 10-Q · Quarterly report

    Report date 2025-12-31 · 0001140361-26-004924

  23. 8-K · Current report

    Report date 2026-01-10 · 0001140361-26-000995 · Items 5.02,9.01

  24. 10-Q/A · Quarterly report

    Report date 2025-09-30 · 0001140361-25-042491

  25. 8-K · Current report

    Report date 2025-11-13 · 0001140361-25-041807 · Items 2.02,8.01,9.01

  26. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001140361-25-041804

  27. 8-K · Current report

    Report date 2025-10-23 · 0001140361-25-039020 · Items 8.01,9.01

  28. 8-K · Current report

    Report date 2025-09-18 · 0001140361-25-035337 · Items 8.01,9.01

  29. 8-K · Current report

    Report date 2025-09-12 · 0001140361-25-034845 · Items 5.07

  30. 8-K · Current report

    Report date 2025-08-27 · 0001140361-25-032847 · Items 8.01,9.01

  31. 8-K · Current report

    Report date 2025-08-12 · 0001140361-25-030400 · Items 2.02,9.01

  32. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001140361-25-030398

  33. DEF 14A · Proxy statement

    Report date 2025-09-12 · 0001140361-25-027456

  34. 8-K · Current report

    Report date 2025-06-25 · 0001140361-25-023557 · Items 8.01,9.01

  35. 8-K · Current report

    Report date 2025-06-23 · 0001140361-25-023261 · Items 2.02,9.01

  36. 10-K · Annual report

    Report date 2025-03-31 · 0001140361-25-023259

  37. 8-K · Current report

    Report date 2025-04-09 · 0001140361-25-012944 · Items 8.01,9.01

  38. 8-K · Current report

    Report date 2025-03-03 · 0001140361-25-006659 · Items 8.01,9.01

  39. 10-Q/A · Quarterly report

    Report date 2024-12-31 · 0001140361-25-005051

  40. 8-K · Current report

    Report date 2025-02-13 · 0001140361-25-004157 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 6 transaction rows6PSale: 0 transaction rows0SGrant / award: 8 transaction rows8AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

14 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-23
2026-09-23
Opaleye Management Inc.P · Purchase
Acquired
Common Stock, par value $0.0001 per share5318.02.1
2026-09-21
2026-09-23
Opaleye Management Inc.P · Purchase
Acquired
Common Stock, par value $0.0001 per share9771.02.1
2026-09-17
2026-09-21
NEUGEBOREN EDWARDA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
12200.00.0
2026-09-17
2026-09-21
DAVIS A BRIANA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
n/a0.0
2026-09-17
2026-09-21
Kavuru VimalA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
12200.00.0
2026-09-17
2026-09-21
Kottayil GeorgeA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
12200.00.0
2026-09-09
2026-09-10
Opaleye Management Inc.P · Purchase
Acquired
Common Stock, par value $0.0001 per share5836.02.09
2026-09-09
2026-09-10
Kohli PrashantP · Purchase
Acquired
Common Stock100000.02.14
2026-09-08
2026-09-10
Opaleye Management Inc.P · Purchase
Acquired
Common Stock, par value $0.0001 per share9393.02.1
2026-08-28
2026-09-01
Kohli PrashantA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
267160.00.0
2026-08-28
2026-09-01
Kumar AmreshA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
35760.00.0
2026-08-28
2026-09-01
Macdonald R. LochA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
54690.00.0
2026-08-28
2026-09-01
DelAversano Robert JA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
33660.00.0
2026-08-14
2026-08-19
Opaleye Management Inc.P · Purchase
Acquired
Common Stock, par value $0.0001 per share11608.02.09

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001444192Grace Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Acasti Pharma Inc. · former SEC name · 2008-09-02 to 2024-10-25

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2022-03-31$100.00M$122.00M

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗